Effects of azathioprine and infliximab on mesenchymal stem cells derived from the bone marrow of rats in vitro

Molecular Medicine Reports

Volumn 9, Issue 3, 2014, Pages 1005-1012

  Huang, Hua Rong ^a   Zan, Hui ^a   Lin, Ying ^a   Zhong, Ying Qiang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Azathioprine; Infliximab; Mesenchymal stem cell; Rat

Indexed keywords

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; APOPTOSIS; AZATHIOPRINE; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; G1 PHASE CELL CYCLE CHECKPOINTS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MESENCHYMAL STROMAL CELLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84893859041     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1905     Document Type: Article

References (28)

1. Beyer Nardi N and da Silva Meirelles L: Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol 174: 249-282, 2006.
2. Li YP, Paczesny S, Lauret E, et al: Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 180: 1598-1608, 2008.
3. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI and West AB: Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 277: C183-C201, 1999.
4. Lazebnik LB, Konopliannikov AG, Kniazew OV, et al: Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory disease. Ter Arkh 82: 38-43, 2010 (In Russian).
5. Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Büscher D and Delgado M: Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58: 929-939, 2009.
6. Suarez-Almazor ME, Spooner C and Belseck E: Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev 4: CD001461, 2000.
7. Sandborn WJ: Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol (Suppl 225): 92-99, 1998.
8. Patel AA, Swerlick RA and McCall CO: Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 55: 369-389, 2006.
9. Rumbo C, Emerick KM, Emre S and Shneider BL: Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr 35: 391-398, 2002.
10. Abu-Shakra M and Shoenfeld Y: Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 10: 152-153, 2001.
11. Tiede I, Fritz G, Strand S, et al: CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111: 1133-1145, 2003.
12. Waters OR and Lawrance IC: Understanding the use of immunosuppressive agents in the clinical management of IBD. Curr Drug Targets 12: 1364-1371, 2011.
13. Chevaux JB, Peyrin-Biroulet L and Sparrow MP: Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis 17: 1428-1435, 2011.
14. Oh CJ, Das KM and Gottlieb AB: Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 42: 829-830, 2000.
15. Maini R, St Clair EW, Breedveld F, et al: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939, 1999.
16. Braun J and Sieper J: Ankylosing spondylitis. Lancet 369: 1379-1390, 2007.
17. Yamamoto-Furusho JK: Current and future biological treatments in inflammatory bowel disease. In: Gene Therapy Applications. Kang C (ed). InTech, Rijeka, pp363-374, 2011.
18. Van den Brande JM, Braat H, van den Brink GR, et al: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774-1785, 2003.
19. Efron PA and Moldawer LL: Cytokines and wound healing: the role of cytokine and anticytokine therapy in the repair response. J Burn Care Rehabil 25: 149-160, 2004.
20. Böcker W, Docheva D, Prall WC, et al: IKK-2 is required for TNF-alpha-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med (Berl) 86: 1183-1192, 2008.
21. Duijvestein M, Molendijk I, Roelofs H, et al: Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease. Cytotherapy 13: 1066-1073, 2011.
22. Zan H and Zhong YQ: The progress of mesenchymal stem cells in the treatment of inflammatory bowel disease. New Medicine 4: 211-215, 2011 (In Chinese).
23. Fischer UM, Harting MT, Jimenez F, et al: Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 18: 683-692, 2009.
24. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC and Pelletier MP: Stem cell transplantation: the lung barrier. Transplant Proc 39: 573-576, 2007.
25. Lee RH, Pulin AA, Seo MJ, et al: Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5: 54-63, 2009.
26. Lazebnik LB, Kniazev OV, Konopliannikov AG, et al: Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation. Eksp Klin Gastroenterol 11: 3-15, 2010 (In Russian).
27. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A and Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-608, 2003.
28. Sagynbaeva VÉ, Lazebnik LB, Kniazev OV and Efremov LI: Antibodies to infliximab and antigens HLA I-II class as the witnesses of immune response to the biological treatment of inflammatory bowel disease. Eksp Klin Gastroenterol 12: 7-14, 2011 (In Russian).